{"entity":{"id":"rndo-564","kind":"drug","name":"RNDO-564","aka":[],"tldr":"RNDO-564 is an experimental bispecific antibody from Rondo Therapeutics, in phase 1 trials for urothelial cancer, non-small cell lung cancer and head and neck squamous cell cancer and other cancers.","summary":"RNDO-564 is a bispecific antibody (T-cell co-stimulatory engager) from Rondo Therapeutics. A CD28 x Nectin-4 bispecific antibody: one arm binds Nectin-4 on tumour cells, the other gives T cells the CD28 co-stimulatory signal. Its furthest stage is phase 1, for urothelial (bladder) cancer, non-small cell lung cancer, head and neck squamous cell cancer and cervical cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b alone and with pembrolizumab, enrolling by invitation (NCT07218003). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Rondo Therapeutics: rondotx.com","url":"https://www.rondotx.com/"},{"label":"Rondo Therapeutics: rondotx.com","url":"https://www.rondotx.com/"},{"label":"Rondo Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07218003"},{"label":"ClinicalTrials.gov: trials of RNDO-564","url":"https://clinicaltrials.gov/search?intr=RNDO-564"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","tnbc"],"sections":[],"technologies":[],"targets":["cd28","nectin4"],"drugs":[],"companies":["rondo-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07218003"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"RNDO-564","modality":"Bispecific antibody (T-cell co-stimulatory engager)","mechanism":"A CD28 x Nectin-4 bispecific antibody: one arm binds Nectin-4 on tumour cells, the other gives T cells the CD28 co-stimulatory signal.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rndo-564/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}],"company":[{"id":"rondo-therapeutics","kind":"company","name":"Rondo Therapeutics","route":"/companies/rondo-therapeutics/"}],"trial":[{"id":"nct07218003","kind":"trial","name":"RNDO-564 alone or with pembrolizumab","route":"/trials/nct07218003/"}]}}